Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees ...

CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares.

Novo Nordisk's growth in diabetes and obesity care makes it a strong buy. Click here for a full investment analysis of NVO ...

Novo Nordisk faces challenges but offers growth potential through a weight loss pill and global expansion. Read more on why ...

Novo Nordisk A/S (NYSE:NVO) is one of the best falling stocks to buy now. On August 7, HSBC maintained a “Hold” rating on ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

Eli Lilly has rolled out a prefilled pen version of its weight-loss drug Mounjaro at the same price as vials, aiming to ...

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Novo Nordisk and ORA officially seal their partnership to revolutionize obesity care in the Philippines through telehealth.

Response Pharmaceuticals’ drug has helped reduce the amount of weight a patient regains after treatment with glucagon-like ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...